Progesterone and estrogen prevent cisplatin-induced apoptosis of lung cancer cells

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 791-800

  Grott, Matthias ^b   Karakaya, Serkan ^b   Mayer, Frank ^b   Baertling, Fabian ^a   Beyer, Cordian ^a   Kipp, Markus ^a   Kopp, Hans Georg ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

A549 cells; Apoptosis; Cisplatin; Estrogen; Lung cancer; Progesterone

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CISPLATIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; MIFEPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL COUNT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CASPASES; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESTROGENS; HUMANS; LUNG NEOPLASMS; PROGESTERONE;

EID: 84875876670     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Gansler T and Brawley OW: From the editors. CA Cancer J Clin 60: 1, 2010.
2. Janku F, Stewart DJ and Kurzrock R: Targeted therapy in nonsmall cell lung cancer-Is it becoming a reality? Nat Rev Clin Oncol 7: 401-414, 2010.
3. Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K and Fukuoka M: Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 46: 247-254, 2004.
4. Novello S and Vavala T: Lung cancer and women. Future Oncology 4: 705-716, 2008.
5. Donington JS, Le QT and Wakelee HA: Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response. Clin Lung Cancer 8: 22-29, 2006.
6. Hsu LH, Chu NM, Liu CC, Tsai SYC, You DL, Ko JS, Lu MC and Feng AC: Sex-associated differences in non-small cell lung cancer in the new era: Is gender an independent prognostic factor? Lung Cancer 66: 262-267, 2009.
7. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK and Potti A: Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24: 59-63, 2006.
8. Hampton T: Lung Cancer Mortality Higher in Women Who Used Combination Hormone Therapy. JAMA 302: 615-616, 2009.
9. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O'Sullivan MJ, Ockene JK, Chen C and Hubbell FA: Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): A post-hoc analysis of a randomised controlled trial. Lancet 374: 1243-1251, 2009.
10. Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, Honma S, Evans DB, Hayashi S, Kondo T and Sasano H: Intratumoral estrogens and estrogen receptors in human nonsmall cell lung carcinoma. Clin Cancer Res 14: 4417-4426, 2008.
11. Abe K, Miki Y, Ono K, Mori M, Kakinuma H, Kou Y, Kudo N, Koguchi M, Niikawa H, Suzuki S, Evans DB, Sugawara S, Suzuki T and Sasano H: Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol 41: 190-198, 2010.
12. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM and Pietras RJ: Aromatase inhibitors in human lung cancer therapy. Cancer Res 65: 11287-11291, 2005.
13. Mah V, Seligson DB, Li A, Marquez DC, Wistuba II, Elshimali Y, Fishbein MC, Chia D, Pietras RJ and Goodglick L: Aromatase expression predicts survival in women with early-stage nonsmall cell lung cancer. Cancer Res 67: 10484-10490, 2007.
14. Marquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, and Pietras RJ: Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann NY Acad Sci 1155: 194-205, 2009.
15. Fasco MJ, Hurteau GJ and Spivack SD: Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 188: 125-140, 2002.
16. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y and Ogawa J: Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 11: 5084-5089, 2005.
17. Mollerup S, Jorgensen K, Berge G and Haugen A: Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37: 153-159, 2002.
18. Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG and Klinge CM: Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer 13: 113-134, 2006.
19. Nose N, Uramoto H, Iwata T, Hanagiri T and Yasumoto K: Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFRTKI for adenocarcinoma of the lung. Lung Cancer 2010.
20. Olivo-Marston SE, Mechanic LE, Mollerup S, Bowman ED, Remaley AT, Forman MR, Skaug V, Zheng YL, Haugen A and Harris CC: Serum estrogen and tumor-positive estrogen receptoralpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis 31: 1778-1786, 2010.
21. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O and Fishbein M: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70: 372-381, 2005.
22. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, Eriksson U and Pietras K: Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 69: 369-378, 2009.
23. Marquez-Garban DC and Pietras RJ: Estrogen-signaling pathways in lung cancer. Adv Exp Med Biol 617: 281-289, 2008.
24. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L and Pietras RJ: Estrogen receptor signaling pathways in human nonsmall cell lung cancer. Steroids 72: 135-143, 2007.
25. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S and Siegfried JM: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62: 2141-2150, 2002.
26. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte SM and Siegfried JM: Pilot study of gefitinib and fulvestrant in the treatment of postmenopausal women with advanced non-small cell lung cancer. Lung Cancer 64: 51-59, 2009.
27. Ishibashi H, Suzuki T, Suzuki S, Niikawa H, Lu L, Miki Y, Moriya T, Hayashi S, Handa M, Kondo T and Sasano H: Progesterone receptor in non-small cell lung cancer - a potent prognostic factor and possible target for endocrine therapy. Cancer Res 65: 6450-6458, 2005.
28. Raso MG, Behrens C, Herynk MH, Liu SY, Prudkin L, Czburn NC, Woods DM, Tang XM, Mehran RJ, Moran C, Lee JJ and Wistuba II: Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15: 5359-5368, 2009.
29. Check JH, Sansoucie L, Chern J and Dix E: Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res 30: 119-122, 2010.
30. Baertling F, Kokozidou M, Pufe T, Clarner T, Windoffer R, Wruck CJ, Brandenburg LO, Beyer C, and Kipp M: ADAM12 is expressed by astrocytes during experimental demyelination. Brain Res 1326: 1-14, 2010.
31. Kramer M, Dang J, Baertling F, Denecke B, Clarner T, Kirsch C, Beyer C and Kipp M: TTC staining of damaged brain areas after MCA occlusion in the rat does not constrict quantitative gene and protein analyses. J Neurosci Methods 187: 84-89, 2010.
32. Lorenz L, Dang J, Misiak M, Tameh AA, Beyer C and Kipp M: Combined 17beta-oestradiol and progesterone treatment prevents neuronal cell injury in cortical but not midbrain neurones or neuroblastoma cells. J Neuroendocrinol 21: 841-849, 2009.
33. Urcan E, Haertel U, Styllou M, Hickel R, Scherthan H and Reichl FX: Real-time xCELLigence impedance analysis of the cytotoxicity of dental composite components on human gingival fibroblasts. Dent Mater 26: 51-58, 2010.
34. Behl C, Widmann M, Trapp T and Holsboer F: 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Comm 216: 473-482, 1995.
35. Ishida S, Lee J, Thiele DJ and Herskowitz I: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99: 14298-14302, 2002.
36. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
37. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
38. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S and Prentice RL: Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684-1692, 2010.
39. Stinchcombe TE, Bogart J, Wigle DA and Govindan R: Annual Review of Advances in Lung Cancer Clinical Research-A report for the year 2009. J Thorac Oncol 5: 935-939, 2010.
40. Ahmad S: Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers 7: 543-566, 2010.
41. Ang WH, Myint M and Lippard SJ: Transcription inhibition by Platinum-DNA cross-links in live mammalian cells. J Am Chem Soc 132: 7429-7435, 2010.
42. Malinge JM, Giraud-Panis MJ and Leng M: Interstrand crosslinks of cisplatin induce striking distortions in DNA. J Inorg Biochem 77: 23-29, 1999.
43. Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, Hartmann JT, Bokemeyer C and Mayer F: Cellcycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 29: 471-479, 2006.
44. Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75: 173-234, 2010.
45. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K and Akiyama S: Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem 15: 3268-3278, 2008.
46. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM and Dolan ME: Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol 64: 133-142, 2009.
47. Safaei R, Holzer AK, Katano K, Samimi G and Howell SB: The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem 98: 1607-1613, 2004.
48. Xu CX, Jin H and Cho MH: Apoptosis and apoptosis-based therapy in lung cancer. Anticancer Agents Med Chem 9: 952-957, 2009.
49. Okouoyo S, Herzer K, Ucur E, Mattern J, Krammer PH, Debatin KM and Herr I: Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int J Cancer 108: 580-587, 2004.
50. Pietras RJ and Marquez-Garban DC: Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 13: 4672-4676, 2007.
51. Ivanova T, Karolczak M and Beyer C: Estrogen stimulates the mitogen-activated protein kinase pathway in midbrain astroglia. Brain Res 889: 264-269, 2001.
52. Shen H, Yuan Y, Sun J, Gao W and Shu YQ: Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother 64: 88-92, 2010.
53. Beyer C, Pawlak J, and Karolczak M: Membrane receptors for oestrogen in the brain. J Neurochem 87: 545-550, 2003.